Sensitive, reliable and easy-performed laboratory monitoring of eculizumab therapy in atypical hemolytic uremic syndrome

Clinical Immunology

Volumn 160, Issue 2, 2015, Pages 237-243

  Volokhina, Elena B ^a   van de Kar, Nicole C A J ^a   Bergseth, Grethe ^b   van der Velden, Thea J A M ^a   Westra, Dineke ^a   Wetzels, Jack F M ^a   van den Heuvel, Lambertus P ^a,c   Mollnes, Tom Eirik ^b,d,e,f,g  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NORDLAND HOSPITAL   (Norway)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d UNIVERSITY OF TROMSØ   (Norway)

^e NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^f OSLO UNIVERSITY HOSPITAL   (Norway)

^g UNIVERSITY OF OSLO   (Norway)

Author keywords

Complement; Eculizumab; Hemolytic uremic syndrome; Personalized therapy

Indexed keywords

COMPLEMENT COMPONENT C5; ECULIZUMAB; COMPLEMENT INHIBITOR; DIAGNOSTIC KIT; MONOCLONAL ANTIBODY;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT CLASSICAL PATHWAY; COMPLEMENT INHIBITION; CONTROLLED STUDY; FEMALE; HEMOLYTIC UREMIC SYNDROME; HUMAN; LABORATORY; MALE; PATIENT MONITORING; PRIORITY JOURNAL; RELIABILITY; SENSITIVITY AND SPECIFICITY; ATYPICAL HEMOLYTIC UREMIC SYNDROME; DEVICES; DIAGNOSTIC KIT; DOSE RESPONSE; DRUG MONITORING; IMMUNOLOGY; PRESCHOOL CHILD; PROCEDURES; REPRODUCIBILITY; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ATYPICAL HEMOLYTIC UREMIC SYNDROME; CHILD; CHILD, PRESCHOOL; COMPLEMENT ACTIVATION; COMPLEMENT INACTIVATING AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; FEMALE; HUMANS; MALE; REAGENT KITS, DIAGNOSTIC; REPRODUCIBILITY OF RESULTS; YOUNG ADULT;

EID: 84938075988     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2015.05.018     Document Type: Article

References (35)

1. Noris M., Remuzzi G. Atypical hemolytic-uremic syndrome. N. Engl. J. Med. 2009, 361:1676-1687.
2. Westra D., Wetzels J.F., Volokhina E.B., van den Heuvel L.P., van de Kar N.C. A new era in the diagnosis and treatment of atypical haemolytic uraemic syndrome. Neth. J. Med. 2012, 70:121-129.
3. Harboe M., Thorgersen E.B., Mollnes T.E. Advances in assay of complement function and activation. Adv. Drug Deliv. Rev. 2011, 63:976-987.
4. Walport M.J. Complement. First of two parts. N. Engl. J. Med. 2001, 344:1058-1066.
5. Stahl A.L., Vaziri-Sani F., Heinen S., Kristoffersson A.C., Gydell K.H., Raafat R., Gutierrez A., Beringer O., Zipfel P.F., Karpman D. Factor H dysfunction in patients with atypical hemolytic uremic syndrome contributes to complement deposition on platelets and their activation. Blood 2008, 111:5307-5315.
6. Lehtinen M.J., Rops A.L., Isenman D.E., van der Vlag J., Jokiranta T.S. Mutations of factor H impair regulation of surface-bound C3b by three mechanisms in atypical hemolytic uremic syndrome. J. Biol. Chem. 2009, 284:15650-15658.
7. Fremeaux-Bacchi V., Dragon-Durey M.A., Blouin J., Vigneau C., Kuypers D., Boudailliez B., Loirat C., Rondeau E., Fridman WH Complement factor I: a susceptibility gene for atypical haemolytic uraemic syndrome. J. Med. Genet. 2004, 41:e84.
8. Richards A., Kemp E.J., Liszewski M.K., Goodship J.A., Lampe A.K., Decorte R., Muslumanoglu M.H., Kavukcu S., Filler G., Pirson Y., Wen L.S., Atkinson J.P., Goodship T.H. Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:12966-12971.
9. Noris M., Brioschi S., Caprioli J., Todeschini M., Bresin E., Porrati F., Gamba S., Remuzzi G. Familial haemolytic uraemic syndrome and an MCP mutation. Lancet 2003, 362:1542-1547.
10. Esparza-Gordillo J., Goicoechea de Jorge E., Buil A., Carreras B.L., Lopez-Trascasa M., Sanchez-Corral P., Rodríguez de Córdoba S. Predisposition to atypical hemolytic uremic syndrome involves the concurrence of different susceptibility alleles in the regulators of complement activation gene cluster in 1q32. Hum. Mol. Genet. 2005, 14:703-712.
11. Caprioli J., Noris M., Brioschi S., Pianetti G., Castelletti F., Bettinaglio P., Mele C., Bresin E., Cassis L., Gamba S., Porrati F., Bucchioni S., Monteferrante G., Fang C.J., Liszewski M.K., Kavanagh D., Atkinson J.P., Remuzzi G. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood 2006, 108:1267-1279.
12. Fremeaux-Bacchi V., Miller E.C., Liszewski M.K., Strain L., Blouin J., Brown A.L., Moghal N., Kaplan B.S., Weiss R.A., Lhotta K., Kapur G., Mattoo T., Nivet H., Wong W., Gie S., Hurault de Ligny B., Fischbach M., Gupta R., Hauhart R., Meunier V., Loirat C., Dragon-Durey M.A., Fridman W.H., Janssen B.J., Goodship T.H., Atkinson J.P. Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome. Blood 2008, 112:4948-4952.
13. Roumenina L.T., Frimat M., Miller E.C., Provot F., Dragon-Durey M.A., Bordereau P., Bigot S., Hue C., Satchell S.C., Mathieson P.W., Mousson C., Noel C., Sautes-Fridman C., Halbwachs-Mecarelli L., Atkinson J.P., Lionet A., Fremeaux-Bacchi V. A prevalent C3 mutation in aHUS patients causes a direct C3 convertase gain of function. Blood 2012, 119:4182-4191.
14. Volokhina E., Westra D., Xue X., Gros P., van de Kar N., van den Heuvel L. Novel C3 mutation p.Lys65Gln in aHUS affects complement factor H binding. Pediatr. Nephrol. 2012, 27:1519-1524.
15. Goicoechea de Jorge E., Harris C.L., Esparza-Gordillo J., Carreras L., Arranz E.A., Garrido C.A., Lopez-Trascasa M., Sanchez-Corral P., Morgan B.P., Rodríguez de Córdoba S. Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:240-245.
16. Delvaeye M., Noris M., De Vriese A., Esmon C.T., Esmon N.L., Ferrell G., Del-Favero J., Plaisance S., Claes B., Lambrechts D., Zoja C., Remuzzi G., Conway E.M. Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N. Engl. J. Med. 2009, 361:345-357.
17. Jozsi M., Licht C., Strobel S., Zipfel S.L., Richter H., Heinen S., Zipfel P.F., Skerka C. Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency. Blood 2008, 111:1512-1514.
18. Rother R.P., Rollins S.A., Mojcik C.F., Brodsky R.A., Bell L. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat. Biotechnol. 2007, 25:1256-1264.
19. Hill A., Kelly R.J., Hillmen P. Thrombosis in paroxysmal nocturnal hemoglobinuria. Blood 2013, 121:4985-4996.
20. Waters A.M., Licht C. aHUS caused by complement dysregulation: new therapies on the horizon. Pediatr. Nephrol. 2011, 26:41-57.
21. Zuber J., Fakhouri F., Roumenina L.T., Loirat C., Fremeaux-Bacchi V. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat. Rev. Nephrol. 2012, 8:643-657.
22. Wong E.K., Goodship T.H., Kavanagh D. Complement therapy in atypical haemolytic uraemic syndrome (aHUS). Mol. Immunol. 2013, 56:199-212.
23. Legendre C.M., Licht C., Muus P., Greenbaum L.A., Babu S., Bedrosian C., Bingham C., Cohen D.J., Delmas Y., Douglas K., Eitner F., Feldkamp T., Fouque D., Furman R.R., Gaber O., Herthelius M., Hourmant M., Karpman D., Lebranchu Y., Mariat C., Menne J., Moulin B., Nurnberger J., Ogawa M., Remuzzi G., Richard T., Sberro-Soussan R., Severino B., Sheerin N.S., Trivelli A., Zimmerhackl L.B., Goodship T., Loirat C. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N. Engl. J. Med. 2013, 368:2169-2181.
24. Bouts A., Monnens L., Davin J.C., Struijk G., Spanjaard L. Insufficient protection by Neisseria meningitidis vaccination alone during eculizumab therapy. Pediatr. Nephrol. 2011, 26:1919-1920.
25. Struijk G.H., Bouts A.H., Rijkers G.T., Kuin E.A., ten Berge I., Bemelman F.J. Meningococcal sepsis complicating eculizumab treatment despite prior vaccination. Am. J. Transplant. 2013, 13:819-820.
26. Grimnes G., Beckman H., Lappegard K.T., Mollnes T.E., Skogen V. Recurrent meningococcal sepsis in a presumptive immunocompetent host shown to be complement C5 deficient-a case report. APMIS 2011, 119:479-484.
27. van Vuuren B.J., Bergseth G., Mollnes T.E., Shaw A.M. Electroluminescent TCC, C3dg and fB/Bb epitope assays for profiling complement cascade activation in vitro using an activated complement serum calibration standard. J. Immunol. Methods 2014, 402:50-56.
28. Hallstensen R.F., Bergseth G., Foss S., Jaeger S., Gedde-Dahl T., Holt J., Christiansen D., Lau C., Brekke O.L., Armstrong E., Stefanovic V., Andersen J.T., Sandlie I., Mollnes T.E. Eculizumab treatment during pregnancy does not affect the complement system activity of the newborn. Immunobiology 2015, 220:452-459.
29. Ardissino G., Testa S., Possenti I., Tel F., Paglialonga F., Salardi S., Tedeschi S., Belingheri M., Cugno M. Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases. Am. J. Kidney Dis. 2014, 64:633-637.
30. Carr R., Cataland S.R. Relapse of aHUS after discontinuation of therapy with eculizumab in a patient with aHUS and factor H mutation. Ann. Hematol. 2013, 92:845-846.
31. Pu J.J., Sido A. Successful discontinuation of eculizumab therapy in a patient with aHUS. Ann. Hematol. 2014, 93:1423-1425.
32. Cugno M., Gualtierotti R., Possenti I., Testa S., Tel F., Griffini S., Grovetti E., Tedeschi S., Salardi S., Cresseri D., Messa P., Ardissino G. Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome. J. Thromb. Haemost. 2014, 12:1440-1448.
33. Noris M., Galbusera M., Gastoldi S., Macor P., Banterla F., Bresin E., Tripodo C., Bettoni S., Donadelli R., Valoti E., Tedesco F., Amore A., Coppo R., Ruggenenti P., Gotti E., Remuzzi G. Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. Blood 2014, 124:1715-1726.
34. Peffault de Latour R., Fremeaux-Bacchi V., Porcher R., Xhaard A., Rosain J., Cadena Castaneda D., Vieira-Martins P., Roncelin S., Rodriguez-Otero P., Plessier A., Sicre de Fontbrune F., Abbes S., Robin M., Socie G. Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab. Blood 2015, 125:775-783.
35. Blom A.M., Österborg A., Mollnes T.E., Okroj M. Antibodies reactive to cleaved sites in complement proteins enable highly specific measurement of soluble markers of complement activation. Mol. Immunol. 2015, 66:164-170.